Previous research has demonstrated that LPS/IFN‐γ‐treated macrophages are more effective in hepatic fibrosis therapy than untreated or IL‐4‐treated macrophages,[9] indicating that more defined macrophages result in more effective therapy. The gene discussed is IL4; the disease is Hepatic fibrosis.